Teva Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Lt.../ IL0006290147 /
TEVJF
2024-10-30 7:03:17 PM
|
Chg.
-
|
Volume |
Bid- |
Ask- |
Market Capitalization |
Dividend Y. |
P/E Ratio |
17.0000USD
|
-
|
100 Turnover: 1,700 |
-Bid Size: - |
-Ask Size: - |
11.7 bill.USD |
- |
- |
Business description
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions to millions of patients every day. Headquartered in Israel, Teva is the world’s largest generic medicines producer, leveraging its portfolio of more than 1,800 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has a world-leading position in innovative treatments for disorders of the central nervous system, including pain, as well as a strong portfolio of respiratory products. Teva integrates its generics and specialty capabilities in its global research and development division to create new ways of addressing unmet patient needs by combining drug development capabilities with devices, services and technologies.
Management board & Supervisory board
CEO |
Kåre Schultz |
Management board |
Eli Kalif, David M. Stark, Dr. Hafrun Fridriksdottir, Eli Shani, Eric Drapé, Galia Inbar, Lori Queisser, Mark Sabag, Nir Baron, Richard Daniell, Sven Dethlefs |
Supervisory board |
Dr. Sol J. Barer, Amir Elstein, Dr. Perry D. Nisen, Dr. Tal Zaks, Gerald M. Lieberman, Janet S. Vergis, Jean-Michel Halfon, Kåre Schultz, Nechemia J. Peres, Prof. Ronit Satchi-Fainaro, Roberto A. Mignone, Rosemary A. Crane |
Company data
Name: |
Teva Pharmaceuticals Industries Ltd. |
Address: |
5 Basel St.,Petach Tikva 49131, Israel |
Phone: |
+972-3-914-8171 |
Fax: |
+972-3-914-8678 |
E-mail: |
-
|
Internet: |
www.tevapharm.com |
Industry: |
Healthcare |
Sector: |
Pharmaceutical Industry |
Sub sector: |
Pharmaceuticals |
End of financial year: |
12-31 |
Free Float: |
88.20% |
IPO date: |
- |
Company calendar
CW 45 | 2024-11-06
Interim Report 3rd Quarter/9 Months
|